Clinical biomarker for arterial hypertension based on micro-vascular retinal imaging

Projektinformationen

RetinArt

ID Finanzhilfevereinbarung: 652542

DOI 10.3030/652542

Abgeschlossenes Projekt

EK-Unterschriftsdatum 22 Oktober 2014

Startdatum 1 Oktober 2014

Enddatum 31 März 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

IMAGINE EYES SA
France

Ziel

The RetinArt project addresses a major public health issue: cardiovascular (CV) events, which are the leading cause of death in the world. The overall project objective is to validate the arteriolar wall-to-lumen ratio (AWLR), a clinical biomarker of the alterations caused by arterial hypertension (AHT) in small arteries. The clinical validation is expected to prove that assessments of the AWLR enable earlier detection of damage caused by AHT, better prediction of CV risk, and more effective adaptation of AHT therapy to patient.
To measure the AWLR biomarker, Imagine Eyes has developed a new retinal imaging system that uses the eye as a window to the microcirculatory system. This instrumentation provides unparalleled microscopic resolution thanks to a breakthrough adaptive optics technology derived from astrophysics. It enables clinicians, for the first time, to directly visualize the microscopic walls of retinal arterioles and quantify the AWLR using automated segmentation software. The examination procedure is totally non invasive and its reliability has been successfully tested with AHT patients in a hospital environment.
The phase 1 of the RetinArt project is a feasibility study that aims at establishing the methodological and economic validity of the proposed clinical validation, and at planning its future execution. The main deliverables expected from phase 1 are a validation plan and a detailed business plan. These outcomes are essential milestones in the translation of Imagine Eyes technology to a new standard that will help reduce the risk of serious complications in wide numbers of AHT patients.

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › public health
• medical and health sciences › clinical medicine › ophthalmology
• natural sciences › physical sciences › astronomy › astrophysics
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases
• medical and health sciences › basic medicine › neurology

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

IMAGINE EYES SA

• Netto-EU-Beitrag: € 50 000,00
• Adresse: RUE CHARLES DE GAULLE 18 ; 91400 ORSAY ; Frankreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ile-de-France › Ile-de-France › Essonne
• Region: Ile-de-France › Ile-de-France › Essonne
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00